RT Journal Article
SR Electronic
T1 Generation of antibodies against COVID-19 virus for development of diagnostic tools
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.20.20025999
DO 10.1101/2020.02.20.20025999
A1 Li, Maohua
A1 Jin, Ronghua
A1 Peng, Ya
A1 Wang, Cuiyan
A1 Ren, Wenlin
A1 Lv, Fudong
A1 Gong, Sitao
A1 Fang, Feng
A1 Wang, Qianyun
A1 Li, Jianli
A1 Shen, Tong
A1 Sun, Hunter
A1 Zhou, Lei
A1 Cui, Yali
A1 Song, Hao
A1 Sun, Le
YR 2020
UL http://medrxiv.org/content/early/2020/02/25/2020.02.20.20025999.abstract
AB The COVID-19 China coronavirus started in Dec 2019 was challenged by the lack of accurate serological diagnostic tool for this deadly disease to quickly identify and isolate the infected patients. The generation of COVID-19-specific antibodies is essential for such tasks. Here we report that polyclonal and monoclonal antibodies were generated by immunizing animals with synthetic peptides corresponding to different areas of Nucleoprotein (N) of COVID-19. The specificities of the COVID-19 antibodies were assessed by Western Blot analysis against NPs from COVID-19, MERS and SARS. Antibodies were used for immunohistochemistry staining of the tissue sections from COVID-19 infected patient, as a potential diagnostic tool. A Sandwich ELISA kit was quickly assembled for quantitation of the virus/NP of COVID-19 concentrations in the vaccine preparations. Development of POCT is also aggressively undergoing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was also supported by the National Natural Science Foundation of China (NSFC) (81702015), and the National Science and Technology Major Project (2018ZX10733403) to H.S.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.